Fig. 2
From: Development of HPV16 mouse and dog models for more accurate prediction of human vaccine efficacy
Evaluation of the efficacy of compound C216 as a prophylactic vaccine in E7inv/wt mice. A Experimental design. B The fluorescence was acquired using the Cellvizio imaging system with the MiniZ probe at 488 nm. Background fluorescence was corrected by comparing with that at the non-injected control site, for every mouse at days 55 and 57. For each injection point, fluorescence intensity was evaluated with a 30–45 s laps video. Each image of the video was used to calculate the mean fluorescence intensity of each injection point. The corrected fluorescence was calculated according to a ratio between the mean of the fluorescence intensity at the lentiviral injection point and the mean of the fluorescence intensity at the NI point. Finally, the geometric mean of the ratio ± SD was calculated for each group. C E7/HPV16 mRNA was quantified by RT-ddPCR. Expression was normalized with Hprt housekeeping gene as described in [53]. D Total serum IgG and lgG2 were measured by ELISA, the optical density (OD) was obtained at 450 nm and the means of the ODs ± SD were calculated. E T-cell stimulation was evaluated by IFN-γ ELISpot assay. Splenocytes were collected from mice, 9 days after lentiviral injection and stimulated in triplicate with the HPV16 E7 116-2jc peptide. For each mouse, the number of spot-forming cells (SFC) corresponds to the median of the triplicate, corrected with the negative control (DMSO). The mean ± SD of the number of IFN-γ SFC per 106 cells was calculated for the 3 groups. Differences between groups were determined using the Mann–Whitney statistical test. SD: Standard deviation, NS: Non-significant, *p value < 0.05; ** p value < 0.01